Is there clinical evidence supporting the potential benefits of glucagon-like peptide receptor agonists (GLP-1RAs) for the prevention of 13 obesity-associated cancers (OACs)? The gene discussed is GCG; the disease is obesity due to melanocortin 4 receptor deficiency.